347 POSTER The RANK ligand inhibitor OPG-Fc reduces bone lesions and skeletal tumor burden in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models

R.Miller; J.Jones; M.Tometsko; A.Armstrong; J.Canon; E.Trueblood; M.Roudier; W.Dougall

首页> 外文期刊>European Journal of Cancer Supplements >347 POSTER The RANK ligand inhibitor OPG-Fc reduces bone lesions and skeletal tumor burden in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models

【24h】

347 POSTER The RANK ligand inhibitor OPG-Fc reduces bone lesions and skeletal tumor burden in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models

机译：347海报RANK配体抑制剂OPG-Fc减少了MDA-231乳腺癌和PC3前列腺癌实验性溶骨转移模型中的骨病变和骨骼肿瘤负担

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
R.Miller; J.Jones; M.Tometsko; A.Armstrong; J.Canon; E.Trueblood; M.Roudier; W.Dougall;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. [J] . Holland PM, Jones J, Piasecki J, Cancer biology & therapy . 2010,第7期

机译：在乳腺癌骨骼转移模型中，将RANKL抑制剂RANK-Fc和rhApo2L / TRAIL /杜拉明联合治疗可减少骨骼病变和骨骼肿瘤负担。
2. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases [J] . MillerR.E., JonesJ.C., TometskoM., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第3期

机译：在非小细胞肺癌骨转移模型中，RANKL抑制作用可阻止溶骨性病变并减轻骨骼肿瘤负担
3. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer [J] . J J Cody, A A Rivera, G R Lyons, Cancer gene therapy . 2010,第12期

机译：用骨保护蛋白武装复制型腺病毒可减轻乳腺癌溶骨性骨转移小鼠模型中的肿瘤负担
4. Alcohol and prostate cancer skeletal metastases induce osteoclastogenesis through RANK ligand. [D] . Zhang, Jian. 2001

机译：酒精和前列腺癌的骨骼转移通过RANK配体诱导破骨细胞生成。
5. Arming a Replicating Adenovirus with Osteoprotegerin Reduces the Tumor Burden in a Murine Model of Osteolytic Bone Metastases of Breast Cancer [O] . James J. Cody, Angel A. Rivera, Gray R. Lyons, -1

机译：武装复制腺病毒与骨蛋白酶会降低乳腺癌骨转移骨转移菌中的肿瘤负担
6. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis [O] . Pamela M. Holland, Robert Miller, Jon Jones, 2010

机译：用RANKL抑制剂RANK-FC和RHAPO2L / TRAIL / Dulanermin的组合疗法减少了乳腺癌骨骼转移模型中的骨病变和骨骼肿瘤负担
7. Novel Strategy to Inhibit Osteolytic Bone Metastases of Breast Cancer [R] . Douglas, J. T. 2002

机译：抑制乳腺癌骨溶解性骨转移的新策略

347 POSTER The RANK ligand inhibitor OPG-Fc reduces bone lesions and skeletal tumor burden in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models

著录项

相似文献

相关主题

期刊订阅